2 dead and 3 wounded! A few days ago, a safety accident occurred in the workshop of Jiutai Pharmaceutical in Jinzhou City, Liaoning Province, which attracted attention. According to the official report, the accident investigation team is investigating the cause of the accident, and the relevant aftermath work is being carried out in an orderly manner.
Screenshot from "Taihe District Release"
According to the notice issued by the People's Government of Taihe District, Jinzhou City on the 12th, at 0:25 on May 12, 2024, a safety accident broke out in the workshop of Zone A of Jinzhou Xintaiji Fine Chemical Co., Ltd. (affiliated to Jinzhou Jiutai Pharmaceutical Co., Ltd.). At 2:33, the fire at the scene was extinguished, two trapped people died after rescue, and three other injured people are being treated in the hospital, the injuries are minor and not life-threatening.
On the morning of the 13th, Zhongxin Health reporters called a number of contact numbers announced on the official website of Jiutai Pharmaceutical, and only contacted the company's sales staff and pharmacovigilance department staff.
Screenshot of Tianyancha information
Tianyancha information shows that Jiutai Pharmaceutical was established in 1998, and its business scope includes drug production, drug commissioned production, drug import and export, drug retail, drug wholesale, etc. The registered capital of the company is 40.9865 million yuan, the actual controller is Li Kejun, and the legal representative is Li Baiyang.
According to the information on its official website, Jinzhou Jiutai Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise with a production history of more than 70 years. The predecessor of Jinzhou Pharmaceutical No. 1 Factory was founded in 1951 and restructured into Jinzhou Jiutai Pharmaceutical Co., Ltd. in 1998. The company covers an area of 58,000 square meters and has 1,250 employees, including 310 engineering and technical personnel; It has 5 production workshops, 1 R&D center, and 1 holding pharmaceutical commercial company.
The company produces nearly 100 varieties, which are mainly divided into raw materials and preparations. "Chlorhexidine" API is a domestic manufacturer, and the suppository products with it as raw material have formed a series of products covering the whole country; Solid preparation products have formed two series of antipyretic analgesics and digestive system drugs; Pantoprazole sodium for injection is a national fourth-class new drug, which can treat peptic ulcer. The company's gynecological drugs are the "gynecological drug production base" designated by the former State Pharmaceutical Administration.
Screenshot of the information on the official website of Jiutai Pharmaceutical
In addition, the official website also said that Jiutai Pharmaceutical Co., Ltd. is a provincial-level enterprise technology research and development center, and the company's economic indicators have been among the top 100 pharmaceutical manufacturers in China in recent years, and it is one of the key pharmaceutical enterprises in Liaoning Province. In July 2011, the company underwent an asset restructuring. In addition, the company has introduced advanced production equipment from Japan, the United Kingdom, Italy and other countries.
China News Network